tiprankstipranks
Trending News
More News >
Merus NV (MRUS)
NASDAQ:MRUS
US Market
Advertisement

Merus (MRUS) Stock Forecast & Price Target

Compare
519 Followers
See the Price Targets and Ratings of:

MRUS Analyst Ratings

Moderate Buy
16Ratings
Moderate Buy
7 Buy
9 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Merus
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRUS Stock 12 Month Forecast

Average Price Target

$99.23
▲(44.04% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $99.23 with a high forecast of $112.00 and a low forecast of $90.00. The average price target represents a 44.04% change from the last price of $68.89.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","113":"$113","56.75":"$56.8","75.5":"$75.5","94.25":"$94.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$99.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,56.75,75.5,94.25,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.3,69.81538461538462,73.33076923076923,76.84615384615384,80.36153846153846,83.87692307692308,87.3923076923077,90.90769230769232,94.42307692307692,97.93846153846154,101.45384615384616,104.96923076923076,108.48461538461538,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.3,68.83307692307692,71.36615384615385,73.89923076923077,76.43230769230769,78.96538461538461,81.49846153846154,84.03153846153846,86.5646153846154,89.09769230769231,91.63076923076923,94.16384615384615,96.69692307692308,{"y":99.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.3,68.12307692307692,69.94615384615385,71.76923076923077,73.59230769230768,75.41538461538461,77.23846153846154,79.06153846153846,80.88461538461539,82.7076923076923,84.53076923076924,86.35384615384615,88.17692307692307,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.99,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.05,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$112.00Average Price Target$99.23Lowest Price Target$90.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on MRUS
Guggenheim
Guggenheim
$109$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus downgraded to Neutral from Buy at GuggenheimMerus downgraded to Neutral from Buy at Guggenheim
Needham Analyst forecast on MRUS
Needham
Needham
Hold
Downgraded
09/29/25
Merus (MRUS) was downgraded to a Hold Rating at NeedhamWe are downgrading MRUS to Hold following the Genmab press release this morning that itis acquiring MRUS for $97/share in cash, and expects the transaction to close by early in1Q26.
Wells Fargo
$95$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus downgraded to Equal Weight from Overweight at Wells FargoMerus downgraded to Equal Weight from Overweight at Wells Fargo
Citi
$101$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus (MRUS) was downgraded to a Hold Rating at Citi
H.C. Wainwright Analyst forecast on MRUS
H.C. Wainwright
H.C. Wainwright
$85$97
Hold
40.80%
Upside
Downgraded
09/29/25
Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration
BMO Capital Analyst forecast on MRUS
BMO Capital
BMO Capital
$110
Buy
59.67%
Upside
Reiterated
09/29/25
Merus's Strong Clinical Achievements and Potential Genmab Acquisition Drive Buy Rating
LifeSci Capital Analyst forecast on MRUS
LifeSci Capital
LifeSci Capital
$110$97
Hold
40.80%
Upside
Downgraded
09/29/25
Balanced Hold Rating on Genmab's Acquisition of Merus Amid Valuation and Strategic Fit Concerns
William Blair Analyst forecast on MRUS
William Blair
William Blair
Hold
Downgraded
09/29/25
Merus (MRUS) was downgraded to a Hold Rating at William Blair
Canaccord Genuity Analyst forecast on MRUS
Canaccord Genuity
Canaccord Genuity
$67$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus downgraded to Hold from Buy at CanaccordMerus downgraded to Hold from Buy at Canaccord
Barclays Analyst forecast on MRUS
Barclays
Barclays
$112
Buy
62.58%
Upside
Reiterated
09/26/25
Barclays Reaffirms Their Buy Rating on Merus (MRUS)
Truist Financial Analyst forecast on MRUS
Truist Financial
Truist Financial
$88$97
Hold
40.80%
Upside
Downgraded
09/26/25
Merus downgraded to Hold from Buy at TruistMerus downgraded to Hold from Buy at Truist
Roth MKM Analyst forecast on MRUS
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$112
Buy
62.58%
Upside
Initiated
09/17/25
Roth MKM Initiates a Buy Rating on Merus (MRUS)MRUS Initiated Overweight w/$112.00 PT at Barclays
Bank of America Securities Analyst forecast on MRUS
Bank of America Securities
Bank of America Securities
$92
Buy
33.55%
Upside
Reiterated
09/15/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), 4D Molecular Therapeutics (NASDAQ: FDMT) and Oric Pharmaceuticals (NASDAQ: ORIC)
Alliance Global Partners Analyst forecast on MRUS
Alliance Global Partners
Alliance Global Partners
$90
Buy
30.64%
Upside
Initiated
08/25/25
Merus initiated with a Buy at Alliance Global PartnersMerus initiated with a Buy at Alliance Global Partners
Leerink Partners Analyst forecast on MRUS
Leerink Partners
Leerink Partners
$95
Buy
37.90%
Upside
Reiterated
08/06/25
Merus's Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on MRUS
Guggenheim
Guggenheim
$109$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus downgraded to Neutral from Buy at GuggenheimMerus downgraded to Neutral from Buy at Guggenheim
Needham Analyst forecast on MRUS
Needham
Needham
Hold
Downgraded
09/29/25
Merus (MRUS) was downgraded to a Hold Rating at NeedhamWe are downgrading MRUS to Hold following the Genmab press release this morning that itis acquiring MRUS for $97/share in cash, and expects the transaction to close by early in1Q26.
Wells Fargo
$95$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus downgraded to Equal Weight from Overweight at Wells FargoMerus downgraded to Equal Weight from Overweight at Wells Fargo
Citi
$101$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus (MRUS) was downgraded to a Hold Rating at Citi
H.C. Wainwright Analyst forecast on MRUS
H.C. Wainwright
H.C. Wainwright
$85$97
Hold
40.80%
Upside
Downgraded
09/29/25
Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration
BMO Capital Analyst forecast on MRUS
BMO Capital
BMO Capital
$110
Buy
59.67%
Upside
Reiterated
09/29/25
Merus's Strong Clinical Achievements and Potential Genmab Acquisition Drive Buy Rating
LifeSci Capital Analyst forecast on MRUS
LifeSci Capital
LifeSci Capital
$110$97
Hold
40.80%
Upside
Downgraded
09/29/25
Balanced Hold Rating on Genmab's Acquisition of Merus Amid Valuation and Strategic Fit Concerns
William Blair Analyst forecast on MRUS
William Blair
William Blair
Hold
Downgraded
09/29/25
Merus (MRUS) was downgraded to a Hold Rating at William Blair
Canaccord Genuity Analyst forecast on MRUS
Canaccord Genuity
Canaccord Genuity
$67$97
Hold
40.80%
Upside
Downgraded
09/29/25
Merus downgraded to Hold from Buy at CanaccordMerus downgraded to Hold from Buy at Canaccord
Barclays Analyst forecast on MRUS
Barclays
Barclays
$112
Buy
62.58%
Upside
Reiterated
09/26/25
Barclays Reaffirms Their Buy Rating on Merus (MRUS)
Truist Financial Analyst forecast on MRUS
Truist Financial
Truist Financial
$88$97
Hold
40.80%
Upside
Downgraded
09/26/25
Merus downgraded to Hold from Buy at TruistMerus downgraded to Hold from Buy at Truist
Roth MKM Analyst forecast on MRUS
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$112
Buy
62.58%
Upside
Initiated
09/17/25
Roth MKM Initiates a Buy Rating on Merus (MRUS)MRUS Initiated Overweight w/$112.00 PT at Barclays
Bank of America Securities Analyst forecast on MRUS
Bank of America Securities
Bank of America Securities
$92
Buy
33.55%
Upside
Reiterated
09/15/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), 4D Molecular Therapeutics (NASDAQ: FDMT) and Oric Pharmaceuticals (NASDAQ: ORIC)
Alliance Global Partners Analyst forecast on MRUS
Alliance Global Partners
Alliance Global Partners
$90
Buy
30.64%
Upside
Initiated
08/25/25
Merus initiated with a Buy at Alliance Global PartnersMerus initiated with a Buy at Alliance Global Partners
Leerink Partners Analyst forecast on MRUS
Leerink Partners
Leerink Partners
$95
Buy
37.90%
Upside
Reiterated
08/06/25
Merus's Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merus

1 Month
xxx
Success Rate
8/14 ratings generated profit
57%
Average Return
+4.05%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +4.05% per trade.
3 Months
xxx
Success Rate
12/14 ratings generated profit
86%
Average Return
+20.99%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +20.99% per trade.
1 Year
Success Rate
11/13 ratings generated profit
85%
Average Return
+35.65%
reiterated a buy rating 2 months ago
Copying Tara Bancroft's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +35.65% per trade.
2 Years
xxx
Success Rate
18/18 ratings generated profit
100%
Average Return
+85.82%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +85.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRUS Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
28
28
26
8
8
Buy
14
17
15
14
13
Hold
12
10
7
2
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
55
48
24
31
In the current month, MRUS has received 21 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. MRUS average Analyst price target in the past 3 months is 99.23.
Each month's total comprises the sum of three months' worth of ratings.

MRUS Financial Forecast

MRUS Earnings Forecast

Next quarter’s earnings estimate for MRUS is -$1.38 with a range of -$2.22 to -$0.68. The previous quarter’s EPS was -$2.23. MRUS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year MRUS has Preformed in-line its overall industry.
Next quarter’s earnings estimate for MRUS is -$1.38 with a range of -$2.22 to -$0.68. The previous quarter’s EPS was -$2.23. MRUS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year MRUS has Preformed in-line its overall industry.

MRUS Sales Forecast

Next quarter’s sales forecast for MRUS is $8.56M with a range of $2.97M to $12.90M. The previous quarter’s sales results were $8.83M. MRUS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MRUS has Preformed in-line its overall industry.
Next quarter’s sales forecast for MRUS is $8.56M with a range of $2.97M to $12.90M. The previous quarter’s sales results were $8.83M. MRUS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MRUS has Preformed in-line its overall industry.

MRUS Stock Forecast FAQ

What is MRUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Merus NV’s 12-month average price target is 99.23.
    What is MRUS’s upside potential, based on the analysts’ average price target?
    Merus NV has 44.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRUS a Buy, Sell or Hold?
          Merus NV has a consensus rating of Moderate Buy which is based on 7 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Merus NV’s price target?
            The average price target for Merus NV is 99.23. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $112.00 ,the lowest forecast is $90.00. The average price target represents 44.04% Increase from the current price of $68.89.
              What do analysts say about Merus NV?
              Merus NV’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of MRUS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis